NCT06772324View on ClinicalTrials.gov

An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions
Autism Spectrum Disorder
Interventions
DRUG

NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group

Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.

DRUG

NORSPAN Buprenorphine Transdermal Patchs for Lower dose group

The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.

DRUG

NORSPAN Buprenorphine Transdermal Patchs for higher dose group

The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.

Trial Locations (1)

Unknown

Peking University Sixth Hospital, Beijing

All Listed Sponsors
collaborator

Ping An-Shionogi Co., Ltd.

UNKNOWN

lead

Peking University Sixth Hospital

OTHER